pith. sign in

arxiv: 2602.20218 · v3 · submitted 2026-02-23 · 📡 eess.IV · q-bio.QM

Robust Glioblastoma Segmentation and Volumetry Without T2-FLAIR: External Validation of Targeted Dropout Training

Marco \"Ochsner , Lena Kaiser , Robert Stahl , Nathalie L. Albert , Thomas Liebig , Robert Forbrig , Jonas Reis This is my paper

Pith reviewed 2026-05-15 20:26 UTC · model grok-4.3

classification 📡 eess.IV q-bio.QM
keywords glioblastomaMRI segmentationT2-FLAIR dropoutnnU-Netexternal validationvolumetrymissing sequence
0
0 comments X

The pith

Targeted dropout of the T2-FLAIR channel during training lets glioblastoma segmentation models keep high accuracy even when that sequence is missing at test time.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper trains 3D nnU-Net models on BraTS data and tests them on an independent external cohort to check whether deliberately zeroing the T2-FLAIR channel at training time protects performance when the same channel is zeroed at inference. Without this step, overall Dice falls from 95 percent to 81 percent and whole-tumor volumetry shows a large negative bias; with targeted dropout both metrics stay close to the full-protocol results. The authors care about this because many clinical and retrospective scans omit T2-FLAIR for time or safety reasons, so a single model that tolerates the absence would let automated analysis run on far more cases without retraining or imputation.

Core claim

Training with targeted T2-FLAIR dropout preserves median overall DSC at 94.8 percent when the full protocol is present and raises it from 81.0 percent to 93.4 percent when T2-FLAIR is absent, while improving whole-tumor DSC from 60.4 percent to 92.6 percent, 95th-percentile Hausdorff distance from 17.24 mm to 2.45 mm, and volume bias from -45.6 mL to 0.83 mL on external validation.

What carries the argument

Targeted T2-FLAIR dropout, which zeros the T2-FLAIR input channel at both training and inference to simulate sequence absence.

If this is right

  • One model can be used for both complete and incomplete MRI protocols without retraining.
  • Whole-tumor volume estimates become reliable enough for longitudinal tracking even on legacy scans lacking FLAIR.
  • Retrospective multi-center studies can include more patients whose protocols vary.
  • The same dropout strategy may extend to other routinely missing sequences in neuro-oncology.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • Hospitals could deploy a single segmentation service that accepts any combination of the four standard sequences.
  • The approach might reduce reliance on sequence-imputation networks or separate models per protocol variant.
  • Similar targeted dropout could be tested on other tumor types or modalities where one contrast is frequently omitted.

Load-bearing premise

Zeroing the T2-FLAIR channel during training and inference accurately mimics real clinical absence of the sequence without introducing other distribution shifts.

What would settle it

Compare automated segmentations against expert ground truth on a new cohort of glioblastoma patients who truly never received T2-FLAIR for clinical reasons rather than by simulation.

read the original abstract

Objectives: To externally validate targeted T2 fluid-attenuated inversion recovery (T2-FLAIR) dropout for robust automated glioblastoma segmentation and whole-tumor volumetry without T2-FLAIR, while preserving performance when the full MRI protocol is available. Methods: In this retrospective multi-dataset study, 3D nnU-Net models were developed on BraTS 2021 (n=848) and externally validated on an independent University of Pennsylvania glioblastoma cohort (n=403). Models were trained with or without targeted T2-FLAIR dropout, zeroing the T2-FLAIR channel during training. Testing used prespecified T2-FLAIR-present and T2-FLAIR-absent scenarios; the absent scenario was simulated by zeroing the T2-FLAIR channel at inference. The primary endpoint was per-patient overall region-wise Dice similarity coefficient (DSC). Secondary endpoints were region-specific DSC, 95th percentile Hausdorff distance, and Bland-Altman whole-tumor volume bias. Results: In external validation, performance was preserved with the full MRI protocol: overall median DSC was 94.8% (interquartile range [IQR] 90.0%-97.1%) with dropout and 95.0% (IQR 90.3%-97.1%) without dropout. In the T2-FLAIR-absent scenario, targeted dropout improved overall median DSC from 81.0% (IQR 75.1%-86.4%) to 93.4% (IQR 89.1%-96.2%). Whole-tumor DSC improved from 60.4% to 92.6%, whole-tumor 95th percentile Hausdorff distance from 17.24 mm to 2.45 mm, and whole-tumor volume bias from -45.6 mL to 0.83 mL. Conclusions: In an independent external test cohort, targeted T2-FLAIR dropout preserved glioblastoma segmentation performance with the full MRI protocol and substantially reduced whole-tumor segmentation error and volumetric bias when T2-FLAIR was absent. These findings support targeted sequence dropout as a practical robustness strategy for automated glioblastoma analysis in retrospective and heterogeneous clinical workflows.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 2 minor

Summary. The manuscript externally validates targeted T2-FLAIR dropout training for 3D nnU-Net glioblastoma segmentation and volumetry. Models trained on BraTS 2021 (n=848) are tested on an independent UPenn cohort (n=403) under prespecified full-protocol and T2-FLAIR-absent scenarios (the latter simulated by zeroing the T2-FLAIR channel at inference). Primary endpoint is per-patient overall region-wise DSC; secondary endpoints include region-specific DSC, 95th-percentile Hausdorff distance, and Bland-Altman whole-tumor volume bias. Key findings: performance is preserved with full protocol (median DSC ~95% with or without dropout), while dropout yields large gains in the absent scenario (overall DSC 81.0% to 93.4%, whole-tumor DSC 60.4% to 92.6%, volume bias -45.6 mL to 0.83 mL).

Significance. If the results hold, the work demonstrates a practical, low-overhead robustness strategy for automated glioblastoma analysis when T2-FLAIR is unavailable, which is common in retrospective and multi-center clinical data. The large independent external cohort and prespecified test scenarios provide direct empirical support for the central claim of preserved performance with full protocol and substantially reduced error without T2-FLAIR.

major comments (2)
  1. [Methods] Methods (targeted dropout and simulation protocol): The robustness claim for real-world missing-sequence workflows rests on the assumption that zeroing the T2-FLAIR channel at both training and inference produces an input distribution equivalent to genuine clinical non-acquisition. The external-validation experiments apply this simulation to the same UPenn cases used in the full-protocol arm, leaving untested any systematic differences in patient demographics, acquisition parameters on remaining sequences, or correlated artifacts that would arise in actual missing-sequence workflows. This assumption is load-bearing for the conclusion that the method supports 'retrospective and heterogeneous clinical workflows.'
  2. [Results] Results (T2-FLAIR-absent scenario): The headline gains (whole-tumor DSC 60.4% to 92.6%, volume bias -45.6 mL to 0.83 mL) are reported clearly, yet their interpretation as evidence of robustness beyond the exact simulation protocol depends on the validity of the zeroing procedure. No sensitivity analysis or discussion of potential distribution shifts is provided to quantify how much the observed improvements might degrade under real missing-sequence conditions.
minor comments (2)
  1. [Abstract] Abstract and Methods: The precise definition of 'overall region-wise DSC' (which sub-regions are included and how the per-patient aggregate is computed) should be stated explicitly to ensure reproducibility.
  2. [Discussion] Discussion: A dedicated limitations paragraph addressing the simulation's scope and the need for future validation on truly missing T2-FLAIR cases would strengthen the manuscript.

Simulated Author's Rebuttal

2 responses · 1 unresolved

We thank the referee for the constructive feedback and positive recommendation. We address the two major comments point-by-point below, agreeing that the simulation protocol carries assumptions that warrant explicit discussion. We propose targeted revisions to the manuscript to strengthen the limitations section without altering the core results or conclusions.

read point-by-point responses

  1. Referee: [Methods] Methods (targeted dropout and simulation protocol): The robustness claim for real-world missing-sequence workflows rests on the assumption that zeroing the T2-FLAIR channel at both training and inference produces an input distribution equivalent to genuine clinical non-acquisition. The external-validation experiments apply this simulation to the same UPenn cases used in the full-protocol arm, leaving untested any systematic differences in patient demographics, acquisition parameters on remaining sequences, or correlated artifacts that would arise in actual missing-sequence workflows. This assumption is load-bearing for the conclusion that the method supports 'retrospective and heterogeneous clinical workflows.'

    Authors: We agree that zeroing the T2-FLAIR channel constitutes a controlled simulation rather than a direct replication of clinical non-acquisition, and that unmeasured shifts in acquisition parameters or patient characteristics could exist in truly missing-sequence cases. This is a standard proxy used in missing-modality robustness studies, but we acknowledge it is an assumption. In revision we will expand the Discussion to explicitly state this limitation, reference prior work employing similar zeroing protocols, and note that the observed gains (e.g., whole-tumor DSC improvement from 60.4% to 92.6%) are demonstrated under the prespecified simulation on an independent external cohort. We maintain that the large sample size and prespecified testing still provide supportive evidence for retrospective workflows, while clarifying the boundary conditions of the claim. revision: partial

  2. Referee: [Results] Results (T2-FLAIR-absent scenario): The headline gains (whole-tumor DSC 60.4% to 92.6%, volume bias -45.6 mL to 0.83 mL) are reported clearly, yet their interpretation as evidence of robustness beyond the exact simulation protocol depends on the validity of the zeroing procedure. No sensitivity analysis or discussion of potential distribution shifts is provided to quantify how much the observed improvements might degrade under real missing-sequence conditions.

    Authors: We concur that a formal sensitivity analysis quantifying degradation under alternative missing-sequence distributions is absent. Because the external cohort is retrospective and T2-FLAIR absence was simulated rather than observed, we lack the data to perform such an analysis within the current study. In revision we will add a paragraph in the Discussion that (i) describes the zeroing procedure as a proxy, (ii) discusses plausible sources of distribution shift (e.g., scanner-specific contrast or motion artifacts on remaining sequences), and (iii) states that the reported improvements should be interpreted within the simulated setting. We will also flag this as an area for future prospective validation. revision: partial

standing simulated objections not resolved
  • Direct validation on cases with genuinely non-acquired T2-FLAIR sequences (as opposed to simulated zeroing) cannot be performed with the available retrospective external cohort.

Circularity Check

0 steps flagged

No circularity: empirical results from independent external validation

full rationale

The paper reports segmentation performance metrics obtained by training 3D nnU-Net models on the BraTS 2021 dataset (n=848) and evaluating on a fully independent University of Pennsylvania cohort (n=403). Targeted T2-FLAIR dropout is implemented as a training-time channel-zeroing procedure; the reported DSC, Hausdorff, and volume-bias improvements are measured on held-out external cases under prespecified present/absent protocols. No equations, uniqueness theorems, or self-citations are invoked to derive the performance numbers; the central claims rest on direct empirical comparison rather than any reduction of outputs to fitted inputs or self-referential definitions. The simulation of sequence absence is an explicit modeling choice whose validity is external to the derivation chain itself.

Axiom & Free-Parameter Ledger

0 free parameters · 2 axioms · 0 invented entities

The central claim rests on standard assumptions in medical image segmentation and the specific design choice of channel zeroing to simulate missing data.

axioms (2)
  • domain assumption nnU-Net architecture is appropriate for 3D multi-modal brain tumor segmentation
    Invoked as the base model choice for all experiments.
  • ad hoc to paper Zeroing the T2-FLAIR channel during training and inference simulates real-world sequence absence without additional biases
    Core design assumption of the targeted dropout method.

pith-pipeline@v0.9.0 · 5736 in / 1325 out tokens · 82896 ms · 2026-05-15T20:26:20.086985+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

29 extracted references · 29 canonical work pages · 1 internal anchor

  1. [1]

    EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

    Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170-86

    work page 2021

  2. [2]

    RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High - and Low -Grade Gliomas in Adults

    Wen PY, van den Bent M, Youssef G, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High - and Low -Grade Gliomas in Adults. J Clin Oncol. 2023;41(33):5187-99

    work page 2023

  3. [3]

    Inter-rater agreement in glioma segmentations on longitudinal MRI

    Visser M, Müller DMJ, van Duijn RJM, et al. Inter-rater agreement in glioma segmentations on longitudinal MRI. NeuroImage: Clinical. 2019;22:101727

    work page 2019

  4. [4]

    Automated quantitative tumour response assessment of MRI in neuro -oncology with artificial neural networks: a multicentre, retrospective study

    Kickingereder P, Isensee F, Tursunova I, et al. Automated quantitative tumour response assessment of MRI in neuro -oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncol. 2019;20(5):728-40

    work page 2019

  5. [5]

    NRG brain tumor specialists consensus guidelines for glioblastoma contouring

    Kruser TJ, Bosch WR, Badiyan SN, et al. NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J Neurooncol. 2019;143(1):157-66

    work page 2019

  6. [6]

    A review of deep learning for brain tumor analysis in MRI

    Dorfner FJ, Patel JB, Kalpathy-Cramer J, et al. A review of deep learning for brain tumor analysis in MRI. NPJ Precis Oncol. 2025;9(1):2

    work page 2025

  7. [7]

    nnU-Net: a self -configuring method for deep learning - based biomedical image segmentation

    Isensee F, Jaeger PF, Kohl SAA, et al. nnU-Net: a self -configuring method for deep learning - based biomedical image segmentation. Nat Methods. 2021;18(2):203-11

    work page 2021

  8. [8]

    The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)

    Menze BH, Jakab A, Bauer S, et al. The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging. 2015;34(10):1993-2024

    work page 2015

  9. [9]

    The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification

    Baid U, Ghodasara S, Mohan S, et al. The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification. arXiv 2021;arXiv:2107.02314. 13

    work page internal anchor Pith review Pith/arXiv arXiv 2021

  10. [10]

    Modality redundancy for MRI -based glioblastoma segmentation

    De Sutter S, Wuts J, Geens W, et al. Modality redundancy for MRI -based glioblastoma segmentation. Int J Comput Assist Radiol Surg. 2024;19(10):2101-9

    work page 2024

  11. [11]

    Handling Missing MRI Data in Brain Tumors Classification Tasks: Usage of Synthetic Images vs

    Moshe YH, Buchsweiler Y, Teicher M, Artzi M . Handling Missing MRI Data in Brain Tumors Classification Tasks: Usage of Synthetic Images vs. Duplicate Images and Empty Images. J Magn Reson Imaging. 2024;60(2):561-73

    work page 2024

  12. [12]

    Brain tumour segmentation with incomplete imaging data

    Ruffle JK, Mohinta S, Gray R, et al. Brain tumour segmentation with incomplete imaging data. Brain Commun. 2023;5(2):fcad118

    work page 2023

  13. [13]

    Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research

    Lasocki A, Gaillard F . Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research. American Journal of Neuroradiology. 2019;40(5):758-65

    work page 2019

  14. [14]

    Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model

    Conte GM, Weston AD, Vogelsang DC, et al. Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. Radiology. 2021;299(2):313-23

    work page 2021

  15. [15]

    Modality Completion via Gaussian Process Prior Variational Autoencoders for Multi-modal Glioma Segmentation

    Hamghalam M, Frangi AF, Lei B, Simpson AL . Modality Completion via Gaussian Process Prior Variational Autoencoders for Multi-modal Glioma Segmentation. In: de Bruijne M, Cattin PC, Cotin S, et al., eds. Medical Image Computing and Computer Assisted Intervention – MICCAI 2021, 2021// 2021. Cham. Springer International Publishing: 442-52

    work page 2021

  16. [16]

    HeMIS: Hetero-Modal Image Segmentation

    Havaei M, Guizard N, Chapados N, Bengio Y . HeMIS: Hetero-Modal Image Segmentation. In: Ourselin S, Joskowicz L, Sabuncu MR, et al., eds. Medical Image Computing and Computer - Assisted Intervention – MICCAI 2016, 2016// 2016. Cham. Springer International Publishing: 469-77

    work page 2016

  17. [17]

    Segmentation of Brain Tumors Using a Multi-Modal Segment Anything Model (MSAM) with Missing Modality Adaptation

    Xing J, Zhang J. Segmentation of Brain Tumors Using a Multi-Modal Segment Anything Model (MSAM) with Missing Modality Adaptation. Bioengineering (Basel). 2025;12(8)

    work page 2025

  18. [18]

    Brain Tumor Segmentation for Multi-Modal MRI with Missing Information

    Feng X, Ghimire K, Kim DD, et al. Brain Tumor Segmentation for Multi-Modal MRI with Missing Information. J Digit Imaging. 2023;36(5):2075-87

    work page 2023

  19. [19]

    Metrics reloaded: recommendations for image analysis validation

    Maier-Hein L, Reinke A, Godau P, et al. Metrics reloaded: recommendations for image analysis validation. Nat Methods. 2024;21(2):195-212

    work page 2024

  20. [20]

    Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers

    Mongan J, Moy L, Kahn CE, Jr. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. Radiol Artif Intell. 2020;2(2):e200029

    work page 2020

  21. [21]

    The University of Pennsylvania glioblastoma (UPenn -GBM) cohort: advanced MRI, clinical, genomics, & radiomics

    Bakas S, Sako C, Akbari H, et al. The University of Pennsylvania glioblastoma (UPenn -GBM) cohort: advanced MRI, clinical, genomics, & radiomics. Sci Data. 2022;9(1):453

    work page 2022

  22. [22]

    Bakas S, Sako, C., Akbari, H., et al . Multi-parametric magnetic resonance imaging (mpMRI) scans for de novo Glioblastoma (GBM) patients from the University of Pennsylvania Health System (UPENN-GBM) (Version 2) [Data set]. The Cancer Imaging Archive. 2021

    work page 2021

  23. [23]

    Equivalence Tests:A Practical Primer for t Tests, Correlations, and Meta -Analyses

    Lakens D. Equivalence Tests:A Practical Primer for t Tests, Correlations, and Meta -Analyses. Social Psychological and Personality Science. 2017;8(4):355-62

    work page 2017

  24. [24]

    Latent Correlation Representation Learning for Brain Tumor Segmentation With Missing MRI Modalities

    Zhou T, Canu S, Vera P, Ruan S . Latent Correlation Representation Learning for Brain Tumor Segmentation With Missing MRI Modalities. IEEE Transactions on Image Processing. 2021;30:4263-74

    work page 2021

  25. [25]

    Hetero -Modal Variational Encoder -Decoder for Joint Modality Completion and Segmentation

    Dorent R, Joutard S, Modat M, et al. Hetero -Modal Variational Encoder -Decoder for Joint Modality Completion and Segmentation. In: Shen D, Liu T, Peters TM, et al., eds. Medical Image Computing and Computer Assisted Intervention – MICCAI 2019, 2019// 2019. Cham. Springer International Publishing: 74-82

    work page 2019

  26. [26]

    AI-powered segmentation and prognosis with missing MRI in pediatric brain tumors

    Chrysochoou D, Gandhi DB, Adib S, et al. AI-powered segmentation and prognosis with missing MRI in pediatric brain tumors. npj Precision Oncology. 2026;10(1):63

    work page 2026

  27. [27]

    TumorSynth: Integrated Brain Tumor and Tissue Segmentation on Brain MRI Scans of Any Resolution and Contrast

    Wu J, Billot B, Zhao F, et al. TumorSynth: Integrated Brain Tumor and Tissue Segmentation on Brain MRI Scans of Any Resolution and Contrast. Radiol Imaging Cancer. 2026;8(2):e250222

    work page 2026

  28. [28]

    Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

    Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(3):540-57

    work page 2019

  29. [29]

    PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group

    Albert NL, Galldiks N, Ellingson BM, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25(1):e29-e41. 14 Tables Overall Whole Tumor Enhancing Tumor Tumor Core T2-FLAIR drop for training DSC med [Q1-Q3] HD95 med [Q1-Q3] DSC med [Q1-Q3] HD95 med [Q1-Q3] DSC med [Q1-Q3] HD95 med [...

    work page 2024